Expressão imunohistoquímica do marcador tumoral CD34 e P27 como fator prognóstico em adenocarcinoma de próstata clinicamente localizado após prostatectomia radical

Nassif, Aissar Eduardo; Filho, Renato Tambara

doi:10.1590/s0100-69912010000500006

Cited by 18 publications

(10 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is in contrast to numerous earlier studies that either did not identify a significant correlation (10,11,14,18,21,22) or even reported inverse associations (7,8,12,16,19,20,25). Of note, the association with low-grade cancers was limited to the subset of ERG fusion-negative tumors.…”

Section: Discussioncontrasting

confidence: 99%

“…The majority of earlier studies analyzing p27 in prostate cancer were performed prior to the discovery of ERG fusions in 2005 (33), and later studies did not consider the ERG status (20–22). It is possible that variable fractions of ERG fusion-negative or -positive cancers may obscure this association, particularly if only small sample sizes are analyzed.…”

Section: Discussionmentioning

confidence: 99%

“…and -positive (ERG pos.) prostate cancers, as well as in all prostate cancers, according to the criteria used by Tsihlias et al (<25%) and Vlachostergios et al (<70%) (6,20). …”

Section: Figurementioning

confidence: 99%

See 2 more Smart Citations

Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis

et al. 2013

View full text Add to dashboard Cite

The cyclin-dependent kinase inhibitor p27Kip1 has been suggested as a prognostic marker in prostate cancer. The aim of this study was to determine the clinical and prognostic role of p27 expression in hormone-naive prostate cancers. A tissue microarray containing samples from 4,699 prostate cancers with attached pathological, clinical follow-up and molecular data was analyzed for nuclear p27 expression by immunohistochemistry. p27 staining was negative in 18.6%, weak in 33.5%, moderate in 28.4% and strong in 19.5% of 3,701 interpretable cancer spots. Loss of p27 immunostaining was linked to tumors of low Gleason grade (P<0.0001) and ERG fusion-negative cancers (P<0.0001). p27 levels were not associated with other parameters, including tumor stage, nodal stage, preoperative prostate-specific antigen (PSA) levels, surgical margin status and cell proliferation (as measured by the Ki67 labeling index). p27 expression was also unrelated to clinical outcome in all cancers, as well as in the subsets of ERG fusion-positive and -negative cancers. Overall, the present data demonstrated that elevated p27 expression was often unrelated to prostate cancer phenotype. Furthermore, the lack of an effect of the p27 protein levels on PSA recurrence following radical prostatectomy indicated that factors other than p27 expression are likely to be the major determinants of prostate cancer recurrence. However, a subset of ERG-negative, low-grade tumors was frequently characterized by loss of p27, suggesting a role of this alteration for the development of these tumors.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis

et al. 2013

View full text Add to dashboard Cite

show abstract

“…The most recent study of p27 expression after RP in 100 cases of clinically localized PC, also failed to detect any association of the former with biochemical recurrence, although p27 positivity defined as ≥ 40% correlated well with a lower median pre-operative PSA and a lower Gleason score [33]. When p27 expression was examined in a cohort of 53 patients with pT2 stage disease, no correlation with Gleason score was revealed and p27 had no prognostic value in predicting biochemical relapse [34].…”

Section: Discussionmentioning

confidence: 99%

Lack of prognostic significance of p16 and p27 after radical prostatectomy in hormone-naïve prostate cancer

Vlachostergios

Karasavvidou

Kakkas

et al. 2012

J Negat Results BioMed

View full text Add to dashboard Cite

BackgroundLoss of normal cell cycle control is an early event in the evolution of cancer. The expression of cyclin-dependent kinase (CDK) inhibitors p16 and p27 has been previously associated with progression of prostate cancer (PC). 70 patients diagnosed with early stage PCwere treated with radical prostatectomy (RP) at our institution and their tumor specimens were immunohistochemically evaluated for expression of p16 and p27. Available clinical data of time to PSA recurrence were correlated with the examined parameters and combined with pre-operative PSA level, Gleason score and pathological TNM (pT) stage assessment.ResultsNuclear overexpression of p16 was not associated with time to biochemical failure (BF) (p = 0.572). Same was the case for nuclear p27 overexpression (p = 1.000). Also, no significant correlations were found between either p16 or p27, and pre-operative PSA level, pT stage and Gleason grade. pT stage emerged as the only independent prognostic factor for biochemical recurrence (p = 0.01).ConclusionsThese data question previously reported data supporting the prognostic relevance of both p16 and p27 proteins in early PC.

show abstract

“…[12] Previously, both qualitative[13] and quantitative[14] assessments of CD34 IHC stained slides have characterized IHC staining via “hotspots”, i.e. manually selected FOVs; yet, the pitfalls associated with manual FOV selection suggest that hotspot-based predictions may not accurately represent CD34 expression in an entire slide.…”

Section: Introductionmentioning

confidence: 99%

Multi-field-of-view strategy for image-based outcome prediction of multi-parametric estrogen receptor-positive breast cancer histopathology: Comparison to Oncotype DX

Basavanhally

Feldman

Shih

et al. 2012

Journal of Pathology Informatics

View full text Add to dashboard Cite

In this paper, we attempt to quantify the prognostic information embedded in multi-parametric histologic biopsy images to predict disease aggressiveness in estrogen receptor-positive (ER+) breast cancers (BCa). The novel methodological contribution is in the use of a multi-field-of-view (multi-FOV) framework for integrating image-based information from differently stained histopathology slides. The multi-FOV approach involves a fixed image resolution while simultaneously integrating image descriptors from many FOVs corresponding to different sizes. For each study, the corresponding risk score (high scores reflecting aggressive disease and vice versa), predicted by a molecular assay (Oncotype DX), is available and serves as the surrogate ground truth for long-term patient outcome. Using the risk scores, a trained classifier is used to identify disease aggressiveness for each FOV size. The predictions for each FOV are then combined to yield the final prediction of disease aggressiveness (good, intermediate, or poor outcome). Independent multi-FOV classifiers are constructed for (1) 50 image features describing the spatial arrangement of cancer nuclei (via Voronoi diagram, Delaunay triangulation, and minimum spanning tree graphs) in H and E stained histopathology and (2) one image feature describing the vascular density in CD34 IHC stained histopathology. In a cohort of 29 patients, the multi-FOV classifiers obtained by combining information from the H and E and CD34 IHC stained channels were able to distinguish low- and high-risk patients with an accuracy of 0.91 ± 0.02 and a positive predictive value of 0.94 ± 0.10, suggesting that a purely image-based assay could potentially replace more expensive molecular assays for making disease prognostic predictions.

show abstract

Expressão imunohistoquímica do marcador tumoral CD34 e P27 como fator prognóstico em adenocarcinoma de próstata clinicamente localizado após prostatectomia radical

Abstract: the markers CD34 and P27 are associated with events specific to prostate cancer, however, only CD34 was able to determine the possibility of biochemical recurrence.

Cited by 18 publications

References 39 publications

Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis

Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis

Lack of prognostic significance of p16 and p27 after radical prostatectomy in hormone-naïve prostate cancer

Multi-field-of-view strategy for image-based outcome prediction of multi-parametric estrogen receptor-positive breast cancer histopathology: Comparison to Oncotype DX

Contact Info

Product

Resources

About